GC to stop making 1st thrombolytic agent amid poor sales - Korea Biomedical Review

GC to stop making 1st thrombolytic agent amid poor sales  Korea Biomedical Review

GC will stop manufacturing Urokinase, Korea's first thrombolytic agent, after 45 years of its launch due to sluggish sales. Urokinase has indications in treating ...



Comments

Post a Comment

Popular posts from this blog

Celgene Corporation Announces POMALYST® Granted Breakthrough Therapy Designation from FDA for HIV-Positive and Negative Kaposi Sarcoma - Global Banking And Finance Review

Celgene Corporation Announces POMALYST® Granted Breakthrough Therapy Designation from FDA for HIV-Positive and Negative Kaposi Sarcoma    Global Banking And Finance Review Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ...
Read more